Insulin-dependent diabetes mellitus (IDDM) in whites is strongly associated with particular HLA-DQαβ heterodimers composed of a DQα chain with anrginine at residue 52 (Arg52+) combined to a DQβ chain lacking an aspartic acid at residue 57 (Asp57−. With the aim of confirming this association, clarifying which heterodimers account for the highest risk of IDDM and explaining the excess risk of DR3-DQw2/DR4-DQw8,115 unrelated white IDDM patients and 108 unrelated healthy nondiabetic control subjects were studied. With polymerase chain reaction and sequence-specific oligonucleotide probes, both patients and control subjects were typed for their HLA-DQA1 and DQB1 alleles and their DQA1-DQB1 haplotype and genotype frequencies were compared. Four major findings emerged from our analysis. 1) Arg52+ DQα/Asp57− Dβp heterodimers, formed in cis and/r in trans, are strongly associated with susceptibility to IDDM; 97% of patients and 46% of control subjects had at least one such susceptibility heterodimer (relative risk [RR] 32, confidence interval [Cl] 14.25–71.86, P < 10−. 2) The degree of disease susceptibility depends on the number of such DQ heterodimers that a subject can express according to his or her DQA1-DQB1 genotype. The highest RR was observed in patients with four susceptibility DQ heterodimers (RR 41, Cl 17.05–95.9). 3) Only part of the susceptibility DQ heterodimers were significantly increased in patients, conferring IDDM susceptibility of different strength. The strongest association was with the DQA1*0501-DQB1*0302 combination formed in trans position (RR 35.2, Cl 12.88–96.78, P < 10−7). 4) The simultaneous expression of four different susceptibility heterodimers explains the highest risk of DR3-DQw2/DR4-DQw8 heterozygotes. In conclusion, there is a dose effect of cis- and trans-encoded HLA-DQαβ heterodimers in IDDM susceptibility influenced by the diversity of these molecules.
Skip Nav Destination
Article navigation
Original Articles|
March 01 1992
Dose Effect of Cis- and Trans-Encoded HLA-DQαβ Heterodimers in IDDM Susceptibility
Iman Khalil;
Iman Khalil
Institut National de la Sante et de la Recherche Medicale (INSERM) U93, Institut Universitaire d'Hematologie and Laboratory of Immunology and Histocompatibility, Saint Louis Hospital
Paris
INSERM U30, Enfants-Malades Hospital
Paris, France
Search for other works by this author on:
Ingeborg Deschamps;
Ingeborg Deschamps
Institut National de la Sante et de la Recherche Medicale (INSERM) U93, Institut Universitaire d'Hematologie and Laboratory of Immunology and Histocompatibility, Saint Louis Hospital
Paris
INSERM U30, Enfants-Malades Hospital
Paris, France
Search for other works by this author on:
Virginia Lepage;
Virginia Lepage
Institut National de la Sante et de la Recherche Medicale (INSERM) U93, Institut Universitaire d'Hematologie and Laboratory of Immunology and Histocompatibility, Saint Louis Hospital
Paris
INSERM U30, Enfants-Malades Hospital
Paris, France
Search for other works by this author on:
Reem Al-Daccak;
Reem Al-Daccak
Institut National de la Sante et de la Recherche Medicale (INSERM) U93, Institut Universitaire d'Hematologie and Laboratory of Immunology and Histocompatibility, Saint Louis Hospital
Paris
INSERM U30, Enfants-Malades Hospital
Paris, France
Search for other works by this author on:
Laurent Degos;
Laurent Degos
Institut National de la Sante et de la Recherche Medicale (INSERM) U93, Institut Universitaire d'Hematologie and Laboratory of Immunology and Histocompatibility, Saint Louis Hospital
Paris
INSERM U30, Enfants-Malades Hospital
Paris, France
Search for other works by this author on:
Jacques Hors
Jacques Hors
Institut National de la Sante et de la Recherche Medicale (INSERM) U93, Institut Universitaire d'Hematologie and Laboratory of Immunology and Histocompatibility, Saint Louis Hospital
Paris
INSERM U30, Enfants-Malades Hospital
Paris, France
Search for other works by this author on:
Address correspondence and reprint requests to Prof. L. Degos, INSERM Unit 93, Centre Hayem, Hopital Saint-Louis 1, Ave Cl. Vellefaux, 75475 Paris Cedex 10, France.
Diabetes 1992;41(3):378–384
Article history
Received:
August 14 1991
Revision Received:
November 22 1991
Accepted:
November 22 1991
PubMed:
1551498
Citation
Iman Khalil, Ingeborg Deschamps, Virginia Lepage, Reem Al-Daccak, Laurent Degos, Jacques Hors; Dose Effect of Cis- and Trans-Encoded HLA-DQαβ Heterodimers in IDDM Susceptibility. Diabetes 1 March 1992; 41 (3): 378–384. https://doi.org/10.2337/diab.41.3.378
Download citation file:
48
Views